Biological product from natural northern biological raw materials with possible use in the prevention, treatment and remission stages after bacterial and viral infections, including COVID-19

Within the framework of the prospective investigation, we studied and substantiated the application of the natural biological product Betukladin as additional preparation in the complex therapy for treatment of the following diseases: chronic viral hepatitis B with delta agent (CVH B+D), destructive pulmonary tuberculosis with extensive and multidrug resistance (XMDR-TB), and moreover, for prevention and rehabilitation of patients after severe COVID-19. Experimental group included 14, 23, 165 and 196 people, respectively; control group included 217 people. Betukladin is encapsulated ultrafine powder containing a complex of lichen β-oligosaccharides with pharmacons, obtained through mechanical and chemical activation of the Cladonia blastemas and butulin from birch bark. The product demonstrates antiviral, immunomodulating, anticoagulant, antibacterial hepatoprotective, antihypoxant, hypolipidemic, detoxicative activity. The complex of lichen bioactive substances and butulin have previously passed toxicological, preclinical and clinical trials (for a number of pathologies) in the form of nutraceutical products Yagel Detox and Betulin. The use of the biological product has enhanced the efficiency of the complex treatment of patients with CVH B+D. It demonstrated significant increase in the total protein level and albumin, a decrease in the cytolysis of hepatocytes, normalization of the levels of leucocytes, thrombocytes and hemoglobin, improvement of the general condition, quality of sleep and work capacity. The clinical trial of Betukladin in phthisiology revealed its high efficiency in treating XMDR-TB: intoxication symptoms were detected to decrease in 100 % of the patients; abacillation, cavity closure, clinical cure of tuberculosis were revealed in 87–78 % of the patients (control: 60 and 40 %, respectively). The liver values improved by 12–32 % (in control, these values worsened by 10-30%). COVID-19 prevention resulted in the disease rate of 3.0 among the people taking Betukladin, while the disease rate in the control group was 13.1 %. Patients taking the biological product at the stage of rehabilitation after COVID-19 with severe pneumonia showed rapid regression of residual effects of the disease (rapid fatigability, depression, and recovery of work capacity), while in the control group, recuperation lasted for one to three months and had severe forms.

1. Kershengolts B.M., Anshakova V.V., Filippova G.V., Kershengolts E.B. Vliyanie temperaturno-vlazhnostnyih meteorologicheskih usloviy na kachestvennyiy i kolichestvennyiy sostav efirnyih masel polyiney Yakutii // Himiya rastitelnogo syirya. 2009. No. 3. P. 89–94.

2. Kershengolts B.M., Zhuravskaya A.N., Hlebnyiy E.S., Shein A.A., Filippova G.V., Shashurin M.M., Anshakova V.V. Biopreparatyi iz prirodnogo arkticheskogo biosyirya v sohranenii zdorovya naseleniya v usloviyah izmeneniy klimata // Ekologiya cheloveka. 2010. No. 3. P. 8–15.

3. Kershengolts B.M., Remigaylo P.A., Shein A.A. Prirodnyie biologicheski aktivnyie veschestva iz tkaney rasteniy i zhivotnyih Yakutii: osobennosti sostava, novyie tehnologii, dostizheniya i perspektivyi ispolzovaniya v meditsine // Dalnevostochnyiy meditsinskiy zhurnal. 2004. Prilozhenie # 1. P. 25–29.

4. Shashurin M.M., Kershengolts B.M. Kompozitsiya na osnove betulina i sloevisch lishaynikov, obladayuschaya antibakterialnyim, protivovirusnyim i detoksikatsionnyim deystviem // Patent #2710236 ot 25.12.2019, prioritet ot 07.03.2019.

5. Anshakova V.V. Biotehnologicheskaya mehanohimicheskaya pererabotka lishaynikov roda Cladonia. M.: Akademiya estestvoznaniya, 2013. 115 p.

6. Kershengolts B.M. Lishayniki: biotehnologii pererabotki, biopreparatyi na ih osnove Moscow. LAP LAMBERT Academic Publishing, 2016. 100 p.

7. Tolstikov G.A., Flehter O,B., Shults E.E., Baltina L.A., Tolstikov A.G. Betulin i ego proizvodnyie. Himiya i biologicheskaya aktivnost // Himiya v interesah ustoychivogo razvitiya. 2005. Vol. 13. P. 1–30.

8. Pereslavtseva A.V., Galayko N.V. Betulin kak perspektivnyiy istochnik dlya polucheniya protivovirusnyih preparatov // Vestnik Permskogo nauchn. tsentra. 2013. No. 3. P. 34–41.

9. Svidetelstvo o gosudarstvennoy registratsii Rospotrebnadzorom i v stranah EVRAZES BAD k pische «YaGEL’ DETOKS» (poroshok) # RU.77.99.11.003.E.014127.09.12 ot 27.09.2012.

10. «Betulin»(SGRRU.77.99.88.003.E.002099.05.18 i RU.77.99.88.003.E.006199.05.15)

11. Mihaylov M.I., Yuschuk N.D., Malinnikova E.Yu. i dr. Proekt programmy po kontrolyu i likvidatsii virusnyih gepatitov kak problemy obschestvennogo zdorovya v Rossiyskoy Federatsii // Infektsionnyie bolezni: novosti, mneniya, obuchenie. 2018. #7(2). S.52-58.

12. Yuschuk N.D., Klimova E.A., Znoyko O.O. i dr. Virusnyie gepatity: klinika, diagnostika, lechenie. M.: GEOTAR-Media, 2012. 160 p.

13. Sleptsova S.S., Sleptsov S.S., Andreev M.N. i dr. Hronicheskie virusnyie gepatityi i pervichnyiy rak pecheni v Respublike Saha (Yakutiya) // Zhurnal infektologii. 2019. No. 11(4). P. 79–84.

14. Gilman C., Heller T., Koh C. Chronic hepatitis delta: A state-of-the-art review and new therapies // World J. Gastroentero l. 2019. Vol. 25 (4567). P. 795.

15. Heidrich B., Yurdaydın C. et al. HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta // Hepatology. 2014. Vol. 60. P. 87–97

16. Vasileva I.A., Sterlikov S.A., Testov V.V. Effektivnost lecheniya bolnyih tuberkulezom: problemyi i puti resheniya // Tuberkulez i bolezni legkih. 2015. No. 6. P. 146–147.

17. Bespalov V.G., Nekrasova V.B., Iordanishvili A.K. Sovremennyiy vzglyad na biologicheski aktivnyie dobavki k pische i ih ispolzovanie v lechebno-profilakticheskih tselyah v klinicheskoy meditsine // Meditsina. XXI vek. 2007. No. 9. P. 86–94.

18. Enikeev A.H., Enikeeva R.A. Ekstrakt Cetraria islandica (L.) Ach. suhoy, tabletirovannaya forma // Patent RF # 2321419, 2008.

19. Filippova G.V., Pavlov N.G., Shashurin M.M., Kershengolts B.M. Vliyanie biologicheski aktivnyih veschestv iz sloevisch severnyih lishaynikov, ekstragirovannyih razlichnyimi metodami, na biologicheskie svoystva mikobakteriy tuberkuleza // Sibirskiy med. zhurnal. 2008. No. 3. P. 99–103.

20. Vinokurova M.K., Evdokimova N., Pavlov N., Anshakova V., Kershengolts B., Stepanova A., Kubarev E. «Yagel detoks» v kompleksnom lechenii tuberkuleza legkih s mnozhestvennoy lekarstvennoy ustoychivostyu // Biofarmatsevticheskiy zhurnal. 2018. Vol. 10, No. 4. P. 74–79.

21. Vinokurova M.K., Evdokimova N.E., Pavlov N.G., Kershengolts B.M, Anshakova V.V. Sposob primeneniya «Yagel detoks» v kachestve sredstva dlya lecheniya tuberkuleza s mnozhestvennoy lekarstvennoy ustoychivostyu // Patent RF 2673555 ot 28.11.2018, prioritet ot 22.05.2017

22. Ligostaeva Yu.V. Farmakognosticheskoe issledovanie berestyi i perspektivyi ee ispolzovaniya v meditsine. Avtoref. … dis. kand. med. nauk. Novosibirsk. 2015. 24 p.

23. Cevik M., Kuppalli K., Kindrachuk J., Peiris M. Virology, transmission, and pathogenesis of SARS-CoV-2 // BMJ. 2020. Vol. 371. doi:10.1136/bmj.m3862

24. Harrison A.G., Tao Lin, Penghua Wang. Mechanisms of SARS-CoV-2 Transmission and Pathogenesis (англ.) // Trends in Immunology. 2020 (1 December). Vol. 41, No. 12. P. 1100–1115.

25. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19). Vremennyie metodicheskie rekomendatsii. Minzdrav Rossii. Ministerstvo zdravoohraneniya Rossiyskoy Federatsii (Versiya 11 ot 07.05.2021). Moscow, 2021. 225 p.

26. Sleptsova S.S., Struchkova T.F., Kolosova O.N., Shashurin M.M., Zamorschikova O.M., Kershengolts B.M. Effektivnost prirodnogo kompleksa «Betukladin» v kompleksnoy terapii hronicheskogo virusnogo gepatita «B» s delta agentom // Sovremennyie problemyi nauki i obrazovaniya. 2021. No. 1. URL: http://www.science-education.ru/article/view?id=30521

27. Preisig R. Supplements to the editorial «Liver prorection therapy» // Schweiz Rundsch Med Prax. 1970. Vol. 59 (N1559). P. 60.

28. Kiseleva T.L., Smirnova Yu.A. Osnovnyie gruppyi biologicheski aktivnyih soedineniy pischevyih rasteniy. M.: FNKETsTMDL Roszdrava, 2007. P. 69–77.

29. Kwon P.S., Hanseul Oh, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, Fraser K., Jung Joo Hong, Linhardt R.J., Dordick J.S. Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro // Cell Discovery. 2020. Vol. 6. Article number: 50.